Drug Resistance

COSMIC has started to annotate mutations identified in the literature as resistance mutations, including those conferring acquired resistance (after treatment) and intrinsic resistance (before treatment). This is a work in progress which we aim to expand, including the curation of 2 or more drug treatments and responses.

Resistance to targeted drug treatment occurs in some patients following an initial drug response. This can be caused by the development of resistance mutations, such as those in the drug target preventing drug binding. Acquired resistance develops gradually within the tumour where subpopulations of cells may acquire or already have the mutations enabling them to emerge under selective drug pressure. Patients who initially responded to treatment relapse as a result of the emergence of the dominant resistant clone. Screening patients for mutations at tumour recurrence identifies these new mutations which were not present (at detectable levels) in the primary pre-treatment tumour. Functional studies may confirm the role of these secondary mutations in resistance.

Alternative transcripts are also displayed here for genes where reported resistant mutations are not located on the canonical transcript but are on the alternative, and also where reported resistant mutations are located at the same genomic position on both the canonical and alternative transcripts or on overlapping genes and/or fusions and share a COSM id.

Table to view drug and gene mutation frequency

Drug Genes Unique Resistant Samples Unique Resistant Mutations
ImatinibABL1, ABL1_ENST00000318560, KIT, PDGFRA1370189
Tyrosine kinase inhibitor - NSABL1, , ABL1_ENST00000318560, EGFR, EGFR_ENST00000454757 (GRCH38),EGFR_ENST00000455089, EGFR_ENST00000442591 (GRCH37)38671
GefitinibEGFR, EGFR_ENST00000454757 (GRCH38), EGFR_ENST00000442591 (GRCH37), EGFR_ENST000004550892389
ErlotinibEGFR, EGFR_ENST00000454757 (GRCH38), EGFR_ENST00000442591 (GRCH37)845
CrizotinibALK, ALK_ENST00000431873 (GRCh37), ALK_ENST00000618119 (GRCh38), MET, MET_ENST00000397752, MET_ENST000005397047350
Endocrine therapyESR1, ESR1_ENST00000206249, ESR1_ENST00000338799, ESR1_ENST00000406599, ESR1_ENST00000427531, ESR1_ENST00000443427, ESR1_ENST000004564837154
DasatinibABL1, ABL1_ENST000003185606611
Purine AnalogueNT5C2, NT5C2_ENST00000404739, NT5C2_ENST00000423468, NT5C2_ENST000004702995781
IbrutinibBTK, BTK_ENST00000372880 (GRCh37), BTK_ENST00000308731(GRCh38)5118
AfatinibEGFR, EGFR_ENST00000454757 (GRCH38), EGFR_ENST00000442591 (GRCH37), EGFR_ENST00000455089486
OsimertinibEGFR, EGFR_ENST00000454757 (GRCH38), EGFR_ENST00000442591 (GRCH37), EGFR_ENST000004550894862
VemurafenibBRAF, BRAF_ENST00000288602 (GRCh38) 247
CeritinibALK, ALK_ENST00000431873 (GRCh37), ALK_ENST00000618119 (GRCh38)2311
AlectinibALK, ALK_ENST00000431873 (GRCh37), ALK_ENST00000618119 (GRCh38)1814
DabrafenibBRAF, BRAF_ENST00000288602(GRCh38) 154
QuizartinibFLT3, FLT3_ENST00000380982 (GRCh37), FLT3_ENST000005370841314
NilotinibABL1, ABL1_ENST00000318560, KIT1311
LorlatinibALK, ALK_ENST00000431873 (GRCh37), ALK_ENST00000618119 (GRCh38)1111
SorafenibFLT3, FLT3_ENST00000380982 (GRCh37), FLT3_ENST000005370841111
BGJ398FGFR2,FGFR2_ENST00000346997,FGFR2_ENST00000351936,FGFR2_ENST00000356226,FGFR2_ENST00000357555,FGFR2_ENST00000358487, FGFR2_ENST00000360144, FGFR2_ENST00000369056, FGFR2_ENST00000369059, FGFR2_ENST00000369060, FGFR2_ENST00000369061, FGFR2_ENST00000478859929
PemigatinibFGFR2_ENST00000358487 86
BosutinibABL1, ABL1_ENST0000031856077
Sunitinib KIT, PDGFRA, FLT3, FLT3_ENST00000380982 (GRCh37) , FLT3_ENST0000053708467
PD0325901 MAP2K1, MAP2K233
Pembrolizumab JAK1, JAK2, JAK2_ENST00000539801 (GRCh37)34
CapmatinibMET, MET_ENST00000397752, MET_ENST0000053970426
PF-04217903MET, MET_ENST0000039775211
SavolitinibMET, MET_ENST0000039775213
IvosidenibIDH1, IDH1_ENST00000345146,IDH1_ENST00000446179149

Other patients are refractory to drug therapy and have intrinsic, or primary, drug resistance. They show no initial response to a drug treatment because the tumour may have pre-existing resistance mutations.

Tumours which have received drug therapy and have a reported drug response are annotated in COSMIC using a Drug Response Tumour Feature based on RECIST (Response Evaluation Criteria in Solid Tumours) criteria:

    complete response (CR) clinical complete response
    partial response (PR) clinical partial response
    stable disease (SD)* clinical primary non response
    progressive disease (PD) clinical primary non response

In addition, COSMIC uses the following annotations for Drug Responses:

  • -- clinical resistant recurrence (for recurrent tumours displaying drug resistance)
  • -- clinical response - not further specified (i.e. unclear if partial or complete response or where an author has considered stable disease a response*)
  • -- clinical non-response - not further specified (i.e. unclear if primary or acquired (secondary) resistance)
  • -- in vitro resistant (for cell line studies)
  • -- in vitro sensitive (for cell line studies)
  • -- xenograft response (used for partial response, complete response)
  • -- xenograft non response

* Stable disease may be annotated as a “clinical response – not further specified” where stable disease is considered by an author as a positive response to therapy and/or where stable disease has been followed by a relapse.

Acquired resistance mutations will occur in tumours annotated as a resistant recurrence e.g. Imatinib clinical resistant recurrence. A recurrent tumour or a metastatic site has been screened for mutations following relapse after an initial drug response. Only those secondary mutations reported as proven to be associated with resistance or presumed by authors to be associated with resistance, e.g. based on their gene location, are annotated as acquired resistance mutations and not incidental passenger mutations detected in a recurrent tumour.

Intrinsic resistance mutations will occur in tumours annotated as having a primary non response e.g. Imatinib clinical primary non response. Only those mutations reported as associated with resistance are annotated as primary resistance mutations.

Where there is a resistance mutation reported in a tumour but it is not possible to identify it as an intrinsic or acquired mutation the following annotation is used e.g. Imatinib clinical non response - not further specified.

Differing drug doses can affect whether a tumour responds to therapy or not, and therefore our drug response annotations will include noise as a result of the different treatment regimens used on individual patients.

COSMIC v99 includes data for following drugs: Vismodegib, Vemurafenib, Osimertinib, Ceritinib, Erlotinib, Gefitinib, Imatinib, Ibrutinib, Nilotinib, Tyrosine kinase inhibitor - NS, Afatinib, Endocrine therapy, Alectinib, PD0325901, Dasatinib, Crizotinib, Selumetinib, Sunitinib, Dabrafenib, Bosutinib, Brigatinib,Quizartinib, Savolitinib, Capmatinib, PF-04217903, Lorlatinib, Pembrolizumab, Purine Analogue, BGJ398, Pemigatinib and Sorafenib

Follow the links below to the 15 genes with drug resistance data -